Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2025; 17(12): 114390
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.114390
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.114390
Advanced gastric small cell carcinoma with immunotherapy-based treatment: A case report
Xiao-Long Zhang, Digestive Endoscopy Center, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, Jiangsu Province, China
Jing-Yan Zhang, Li Wang, Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China
Ling Xie, Hui Li, Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China
Co-first authors: Xiao-Long Zhang and Jing-Yan Zhang.
Co-corresponding authors: Hui Li and Li Wang.
Author contributions: Li H designed and wrote the case report and performed the literature search; Zhang XL and Xie L assisted in the literature search and wrote the paper; Wang L and Zhang JY participated in the data acquisition.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Li, MD, Doctor, Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine, No. 155 Hanzhong Road, Nanjing 210029, Jiangsu Province, China. lihui19830401@163.com
Received: September 19, 2025
Revised: October 23, 2025
Accepted: November 13, 2025
Published online: December 15, 2025
Processing time: 84 Days and 0.9 Hours
Revised: October 23, 2025
Accepted: November 13, 2025
Published online: December 15, 2025
Processing time: 84 Days and 0.9 Hours
Core Tip
Core Tip: The clinical and pathological characteristics of primary gastric small cell carcinoma (GSCC) resemble those of small cell lung cancer, but it is less sensitive to chemotherapy and has a poor prognosis. Here we report a case of a 67-year-old man who was found to have a primary stage IV GSCC with metastasis to the liver. The patient was treated with chemotherapy combined with a programmed cell death ligand 1 (PD-L1) inhibitor. Whether PD-L1 inhibitors are optimal for metastatic GSCC requires further exploration.